



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



**Date: 29 September 2023**

<b>To</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	<b>To</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
<b>Security Code: 540596</b>	<b>Symbol: ERIS</b>

**SUBJECT: INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)**

Dear Sir/Madam,

We would like to inform that the Company has entered into Term Loan Agreement dated 27 September 2023 to avail the Rupee Term Loan facility amounting to ₹ 212,00,00,000/- (Rupees Two Hundred and Twelve Crores Only) from HDFC Bank Limited (“**Bank/HDFC**”). However, the consolidated net debt of the Company is not expected to be altered due to this development as an equivalent amount is expected to be paid by EOHPL to the Bank towards repayments of outstanding loans over the next fortnight.

In accordance with requirement of regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para B (5) of Part A of Schedule III and SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, details attached herein shall be taken on record.

Thanking You,

**For Eris Lifesciences Limited**

**Milind Talegaonkar**  
**Company Secretary & Compliance Officer**  
**Membership No: A26493**  
**Encl: As above**

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



**Agreements (viz. loan agreement(s) or any other agreement(s) which are binding and not in normal course of business, revision(s) or amendment(s) and termination(s) thereof:**

Sr. No.	Particulars	Details
1.	name(s) of parties with whom the agreement is entered	HDFC Bank Limited (“ <b>Bank/HDFC</b> ”) and Eris Lifesciences Limited (“ <b>Company</b> ”)
2.	purpose of entering into the agreement	<p>The dermatology brands acquired from Glenmark (“<b>Brands</b>”) by the wholly owned subsidiary- Eris Oaknet Healthcare Private Limited (“<b>EOHPL</b>”) on 17<sup>th</sup> January 2023, were assigned in favour of the Holding Company Eris Lifesciences Ltd. (“<b>ELL</b>”) on 3<sup>rd</sup> July 2023, at their book value in pursuance of operational integration. The consideration thereof needs to be paid by ELL to EOHPL. To facilitate that, ELL has availed term loan from HDFC. The funds received from HDFC pursuant to this loan will be used to make payment to EOHPL towards consideration for assignment of Brands.</p> <p>EOHPL, reportedly, shall use the consideration so received for making full repayment of the loans previously availed by it from HDFC for acquiring the Brands.</p>
3.	size of agreement	₹ 212,00,00,000/- (Rupees Two Hundred and Twelve Crores Only)
4.	shareholding, if any, in the entity with whom the agreement is executed	NIL
5.	significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	The Bank shall have a pari-passu charge along with Citi Bank N.A. on the trademarks acquired from Eris Oaknet Healthcare Private Limited.
6.	whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	NA
7.	whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	NA
8.	in case of issuance of shares to the parties, details of issue price, class of shares issued	NA
9.	in case of loan agreements: <ul style="list-style-type: none"> <li>➤ details of lender/borrower,</li> <li>➤ nature of the loan,</li> </ul>	<p>HDFC Bank Limited</p> <p>Rupee Term Loan</p>

**Registered & Corporate Office:**



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



	<ul style="list-style-type: none"> <li>➤ total amount of loan granted/taken,</li> <li>➤ total amount outstanding,</li> <li>➤ date of execution of the loan agreement/sanction letter</li> <li>➤ details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis;</li> </ul>	<p>₹ 212,00,00,000/- (Rupees Two Hundred and Twelve Crores Only)</p> <p>NIL</p> <p>The loan agreement was executed on September 27, 2023.</p> <p>The Bank shall have a pari-passu charge along with Citi Bank N.A. on the trademarks acquired from Eris Oaknet Healthcare Private Limited.</p>
<b>10.</b>	any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	NA
<b>11.</b>	<p>in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s):</p> <ol style="list-style-type: none"> <li>i. name of parties to the agreement;</li> <li>ii. nature of the agreement;</li> <li>iii. date of execution of the agreement;</li> <li>iv. details of amendment and impact thereof or reasons of termination and impact thereof.</li> </ol>	NA

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
 Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867